Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma

Journal of Viral Hepatitis

Volumn 12, Issue 6, 2005, Pages 635-641

  Koskinas, John ^a,b   Petraki, K ^b   Kavantzas, N ^a   Rapti, I ^a   Kountouras, D ^a   Hadziyannis, S ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Dysplastic liver cell changes; Hepatocellular carcinoma; Hepatocellular proliferation; Ki 67; p53; Viral cirrhosis

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CARCINOGENICITY; CELL NUCLEUS; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPLASIA; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LABELING INDEX; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; KI-67 ANTIGEN; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 27444435278     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00635.x     Document Type: Article

References (58)

1. Koike K. transgenic mouse models of viral hepatitis: insight into viral hepatocarcinogenesis. Viral Hepat Rev 1999; 5: 177-203.
2. Nakamoto Y, Guidotti LG, Kuhlen CV et al. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998; 188: 341-350.
3. Idilman R, De Maria N, Colantoni A, Van Thiel DH. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J Viral Hepat 1998; 5: 285-299.
4. Matsubara K, Tokino T. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med 1990; 7: 243-260.
5. Moriya K, Fujie H, Shintani Y et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-1067.
6. Machida K, Cheng KT, Sung VM et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci USA 2004; 101(12): 4262-4267.
7. Ledda-Columbano GM, Shinozuka H, Katyal SL et al. Cell proliferation, cell death and hepatocarcinogenesis. Cell Death Diff 1996; 3: 17-22.
8. Wong N, Lai P, Lee S-W et al. Assessment of genetic changes in hepatocellular carcinomas by comparative genomic hybridization analysis. Relationship to disease stage, tumor size and cirrhosis. Am J Pathol 1999; 154: 37-43.
9. Tabor E. The role of tumor suppressor genes in the development of hepatocellular carcinoma. In: Okuda K, Tabor E, eds. Liver Cancer. New York: Churchill Livingstone, 1997: 89-95.
10. Cox LS, Lane DP. Tumor suppressors, kinases and clumps: how p53 regulates the cell cycle in response to DNA damage. Bioassays 1995; 17: 501-508.
11. Jacks T, Weinberg RA. Cell cycle control and its watchman. Nature 1996; 381: 643-644.
12. Porter PL, Gown A, Kramp SG et al. Widespread p53 overexpression in human malignant tumors: an immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol 1992; 140: 145-153.
13. Livni N, Eid A, Ilan Y et al. p53 expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer 1995; 75: 2420-2426.
14. Qin G, Su J, Ning Y et al. p53 expression in patients with hepatocellular carcinoma from the high incidence area of Guangxi, Southern China. Cancer Lett 1997; 121: 203-210.
15. Skopelitou A, Hadjiyannakis M, Alexopoulou V et al. p53 expression in hepatocellular carcinoma in Greece. Correlation with epidemiological and histopathological data. Pathol Res Pract 1996; 192: 1100-1106.
16. Bourdon JC, d'Errico A, Paterlini P et al. P53 protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation. Gastroenterology 1995; 108: 1176-1182.
17. Tannapfel A, Wasner M, Krause K et al. Expression of p53 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst 1999; 91: 1154-1158.
18. Jaskiewitcz K, Banach L, Izycka E. Hepatocellular carcinoma in young patients: histology, cellular differentiation, HBV infection and oncoprotein p53. Anticancer Res 1995; 15: 2723-2725.
19. Kang YK, Kim CJ, Kim HO et al. P53 mutation and overexpression in hepatocellular carcinoma and dysplastic nodules in the liver. Virchows Arch 1998; 423: 27-32.
20. Farber E. On cells of origin of liver cell cancer. In: Sirica AE, ed. The Role of Cell Types in Hepatocarcinogenesis. Boca Raton, FL: CRC, 1992: 1-28.
21. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22: 983-993.
22. Anthony PP, Ishak K, Nayak NC. The morphology of cirrhosis. J Clin Pathol 1978; 31: 395-414.
23. Gibson JB, Sobin LH. Histological typing of tumors of the liver, biliary tract and pancreas. International histological classification of tumors number 20. WHO 1978; 12-30.
24. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
25. Farinati F, Cardin R, D'Errico A et al. Hepatocyte proliferative activity in chronic liver damage assessed by the monoclonal antibody MIB1 Ki67 in archival material: the role of etiology, disease activity, iron and lipid peroxidation. Hepatology 1996; 23: 1468-1475.
26. Ng IO, Na J, Lai EC, Fan ST, Ng M. Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB-1. A comparison with proliferating cell nuclear antigen. Am J Clin Pathol 1995; 104: 313-318.
27. Wells SJ, DeRose PB, Cohen C. Image cytometric comparison of proliferating cell nuclear antigen and MIB-1 staining in hepatocellular carcinoma and adjacent liver tissue. Cytometry 1996; 26: 198-203.
28. Chisari FV. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology 1995; 22: 1316-1325.
29. Hagen TM, Huang S, Curnutte J et al. Extensive oxidative DNA damage in hepatocytes in transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Med Sci 1994; 91: 12808-12812.
30. Raptis I, Koskinas J, Emmanouil T, Hadziyannis S. Changing relative roles of hepatitis B and C viruses in hepatocellular carcinoma in Greece. Epidemiological and clinical observations. J Viral Hepat 2003; 10: 450-454.
31. Resnick RH, Koff R. Hepatitis C-related hepatocellular carcinoma. Arch Intern Med 1993; 153: 1672-1677.
32. Ferrell LD, Crawford JM, Dhillon AP et al. Proposal for standardized criteria for the diagnosis of benign, borderline and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol 1994; 17: 1113-1123.
33. Borzio M, Bruno S, Roncalli M et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 1995; 108: 812-817.
34. Borzio M, Trere D, Borzio F et al. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. J Clin Pathol Mol Pathol 1998; 51: 96-101.
35. Le Bail B, Bernard PH, Carles J et al. Prevalence of liver cell dysplasia and association with HCC in a series of 100 cirrhotic liver explants. J Hepatol 1997; 27: 835-842.
36. Ballardini G, Groff P, Zoli M et al. Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation. J Hepatol 1994; 20: 218-222.
37. Donate MF, Arosio E, Del Ninno E et al. High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity. Hepatology 2001; 34: 523-528.
38. Lee RG, Tsamandas AC, Demetris AJ. Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology 1997; 26: 1415-1422.
39. Thung SN, Hytiroglou P, Fiel I, Theise N. Preneoplastic lesions in chronic hepatitis C. Princess Takamatsu Symp 1995; 25: 171-178.
40. Makino Y, Shiraki K, Sugimoto K et al. Histological features of cirrhosis with hepatitis C virus for prediction of hepatocellular carcinoma development: a prospective study. Anticancer Res 2000; 20: 3709-3716.
41. La Bail B, Belleannee G, Bernard F-H et al. Adenomatous hyperplasia in cirrhotic livers: histological evaluation, cellular density, and proliferative activity of 35 macronodular lesions in the cirrhotic explants of 10 adult French patients. Hum Pathol 1995; 26: 897-906.
42. Adachi E, Hashimoto H, Tsuneyoshi M. Proliferating cell nuclear antigen in hepatocellular carcinoma and small cell liver dysplasia. Cancer 1993; 72: 2902-2909.
43. Tiniakos DG, Brunt EM. Proliferating cell nuclear antigen and Ki-67 labeling in hepatocellular nodules: a comparative study. Liver 1999; 19: 58-68.
44. Nakamura T, Hayama M, Sakai T et al. Proliferative activity of hepatocytes in chronic viral hepatitis as revealed by immunohistochemistry for proliferating cell nuclear antigen. Human Pathol 1993; 24: 750-753.
45. Farinati F, Cardin R, Fiorentino M et al. Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease. J Viral Hepat 2001; 8: 34-40.
46. Ronenberg B, Ruester B, Lee JH et al. Hepatocellular carcinoma in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels. J Hepatol 2000; 33: 640-647.
47. Dutta U, Kench J, Byth K et al. Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C. Hum Pathol 1998; 29: 1279-1284.
48. Tarao K, Ohakawa S, Shimizu A et al. Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus positive cirrhotic patients. Cancer 1994; 73: 1149-1154.
49. Derenzini M, Trere D, Oliveri F et al. Is high AgNOR quantity in hepatocytes associated with increased risk of hepatocellular carcinoma in chronic liver disease? J Clin Pathol 1993; 46: 727-729.
50. Ito Y, Matsuura N, Sakon M et al. Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer 1999; 81: 747-751.
51. King KL, Hwang JJ, Chau GY et al. Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1998; 13: 273-279.
52. Watanuki A, Ohwada S, Fukusato T et al. Low MIB-1 labeling index in anti-HCV positive hepatocellular carcinoma. Int J Oncol 1998; 13: 1017-1022.
53. Ojanguren I, Ariza A, Castella EM et al. p53 immunoreactivity in hepatocellular adenoma, focal nodular hyperplasia, cirrhosis and hepatocellular carcinoma. Histopathology 1995; 26: 63-68.
54. Cohen C, DeRose PB. Immunohistochemical p53 expression in hepatocellular carcinoma and liver cell dysplasia. Mod Pathol 1994; 7: 536-539.
55. Yamagata M, Masaki T, Okudaira T et al. Small hyperechoic nodules in chronic liver diseases include hepatocellular carcinomas with low cyclin D1 and Ki-67 expression. Hepatology 1999; 29: 1722-1729.
56. Wu PC, Lau VK, Fang JW et al. Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinoma. Liver 1999; 19: 444-451.
57. Edamoto Y, Hara A, Biernat W et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 2003; 106: 334-341.
58. Mitsumoto Y, Nakajima T, Marutani M et al. Loss of p53 transcriptional activity in hepatocellular carcinoma evaluated by yeast-based functional assay: comparison with p53 immunohistochemistry. Hum Pathol 2004; 35: 350-356.